Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
International Journal of MS Care|August 24, 2016
A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple SclerosisTheodore R Brown, Virginia I Simnad
International Journal of MS Care|July 2, 2020
A Topical Adhesive Containing Anesthetic and Heating Components to Reduce Injection Pain with Subcutaneous Multiple Sclerosis Medications: A Pilot StudyTheodore R Brown, Virginia I Simnad
Magnetic Resonance Imaging|July 11, 2006
Increased glucose concentration in the hippocampus in early Alzheimer's disease following oral glucose ingestionAndreana P Haley, Jack Knight-Scott, Virginia I Simnad, et al.
Magnetic Resonance Imaging|December 13, 2002
Constrained modeling for spectroscopic measurement of bi-exponential spin-lattice relaxation of water in vivoJack Knight-Scott, Elana Farace, Virginia I Simnad, et al.
Neuroscience Letters|May 26, 2004
Shortening of hippocampal spin-spin relaxation time in probable Alzheimer's disease: a 1H magnetic resonance spectroscopy studyAndreana P Haley, Jack Knight-Scott, Kathleen L Fuchs, et al.
International Journal of MS Care|April 21, 2015
A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosisTheodore R Brown, April Slee
Physical Medicine and Rehabilitation Clinics of North America|May 17, 2005
Exercise and rehabilitation for individuals with multiple sclerosisTheodore R Brown, George H Kraft
Magnetic Resonance Imaging|October 16, 2003
Molality as a unit of measure for expressing 1H MRS brain metabolite concentrations in vivoJack Knight-Scott, Andreana P Haley, Sarah R Rossmiller, et al.
International Journal of MS Care|October 23, 2014
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosisAndrew D Goodman, Theodore R Brown, Randall T Schapiro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Pageof 2